Indaptus Therapeutics Change in Accounts Payable 2015-2025 | INDP

Indaptus Therapeutics change in accounts payable from 2015 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

Indaptus Therapeutics Change in Accounts Payable 2015-2025 | INDP

Indaptus Therapeutics change in accounts payable from 2015 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$76.3B
Zoetis (ZTS)$66.2B
Takeda Pharmaceutical (TAK)$45.9B
Daiichi Sankyo, - (DSNKY)$45.5B
BeOne Medicines - (ONC)$32.3B
Sandoz Group AG (SDZNY)$25B
Summit Therapeutics (SMMT)$19.5B
Merck (MKKGY)$16.7B
Shionogi (SGIOY)$14.2B
United Therapeutics (UTHR)$13.2B
Neurocrine Biosciences (NBIX)$13.1B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.5B
Stevanato Group S.p.A (STVN)$7.5B
Corcept Therapeutics (CORT)$7.5B
Madrigal Pharmaceuticals (MDGL)$7.4B
Grifols, S.A (GRFS)$6.8B
Ionis Pharmaceuticals (IONS)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Hypermarcas (HYPMY)$3.1B
Crinetics Pharmaceuticals (CRNX)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
NewAmsterdam Pharma (NAMS)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B
ARS Pharmaceuticals (SPRY)$1.8B